Bausch Health Companies Inc. (BHC) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $6.17, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%).
Bausch Health is a global specialty pharma and medical device company with five segments: Salix (GI, led by Xifaxan at ~85% of Salix revenues), International, Solta Medical (aesthetic devices), Diversified, and ~88%-owned Bausch + Lomb (eye health). 2025 revenues were $10.27B;... Read more
Sell if holding. At $6.17, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%). Chart setup: Death cross but MACD improving, RSI 68. Score 6.1/10, moderate confidence.
Passes 5/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXifaxan85%10-K Item 1: 'Sales of the Xifaxan® product line currently represent approximately 85% of the Salix segment revenues'
- HIGHProductArestin95%10-K Item 1: 'Arestin®...represents approximately 95% of Dentistry revenues'
Material Events(8-K, last 90d)
- 2026-03-02Item 5.02LOWBausch Health amended 2023 PSU awards for CEO Thomas Appio and Seana Carson to settle in cash rather than stock on the March 3, 2026 vesting date. Routine compensatory arrangement modification; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $6.17, A.R:R 0.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%). Chart setup: Death cross but MACD improving, RSI 68. Prior stop was $5.76. Score 6.1/10, moderate confidence.
Take-profit target: $6.59 (+6.4% upside). Prior stop was $5.76. Stop-loss: $5.76.
Concentration risk — Product: Xifaxan (85.0%); Concentration risk — Product: Arestin (95.0%); Thin upside margin: 6.3%.
Bausch Health Companies Inc. trades at a P/E of 13.3 (forward 1.4). TrendMatrix value score: 8.7/10. Verdict: Sell.
9 analysts cover BHC with a consensus score of 2.4/5. Average price target: $8.
What does Bausch Health Companies Inc. do?Bausch Health is a global specialty pharma and medical device company with five segments: Salix (GI, led by Xifaxan at...
Bausch Health is a global specialty pharma and medical device company with five segments: Salix (GI, led by Xifaxan at ~85% of Salix revenues), International, Solta Medical (aesthetic devices), Diversified, and ~88%-owned Bausch + Lomb (eye health). 2025 revenues were $10.27B; Xifaxan generated $2.2B.